Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced the initiation of two phase III clinical trials...
List view / Grid view
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced the initiation of two phase III clinical trials...
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has expanded its biopharmaceutical cell line development services...
14 December 2011 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the company intends to invest 70 million Euro to expand its manufacturing plant in the Zhangjiang High-Tech Park in Shanghai...
9 December 2011 | By Boehringer Ingelheim
The final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335...
1 December 2011 | By Boehringer Ingelheim
AVEO & Boehringer Ingelheim enter into an agreement...
27 October 2011 | By Boehringer Ingelheim
Update across Europe on Pradaxa®...
5 October 2011 | By Gilead Sciences
Gilead Sciences, Inc. and Boehringer Ingelheim have entered into a licensing agreement...
27 September 2011 | By Boehringer Ingelheim
Results from a Phase I/II study...
26 September 2011 | By Boehringer Ingelheim
Boehringer Ingelheim will establish a new separate business for the development and commercialization of own biosimilars...
22 September 2011 | By Boehringer Ingelheim
Phase II clinical trial results...
21 September 2011 | By Boehringer Ingelheim
Once-daily Viramune® (nevirapine) prolonged-release has received approval...
7 September 2011 | By Boehringer Ingelheim
Boehringer Ingelheim wins the '2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award'...
30 August 2011 | By Boehringer Ingelheim
Two phase II studies investigating afatinib are now open for recruitment...
New data from two RE-LY® trial subgroup analyses show that dabigatran etexilate 150mg bid consistently reduces the risk of stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet [1] or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil. [2] The relative benefits…
25 August 2011 | By Eli Lilly and Company, Boehringer Ingelheim
Linagliptin is the only DPP-4 inhibitor to be approved at one dosage strength for adults with type 2 diabetes in Europe, without any need for dose adjustments...